The STRATEC Group

STRATEC designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

The market theoretically accessible to STRATEC amounts to approximately 5 billion US dollars per annum. Although this market is still largely catered for by diagnostics companies’ own instrumentation departments, these companies are increasingly outsourcing their activities, thus offering additional new potential for STRATEC to increase its business volume.

In this environment, STRATEC succeeds in progressively acquiring further leading diagnostics companies as partners, thus ensuring a high level of marketing and market performance. It is this symbiosis with the key players in the diagnostics and biotechnology industries which represents the key pillar of STRATEC’s business model.

The development of integrated, fully automated analyzer systems meeting customers’ requirements demands a very high degree of expertise in the areas of engineering, biological, medical and chemical sciences. In view of this, the technical expertise of STRATEC’s workforce, 50% of which are employed in R&D, represents a valuable resource deployed to the advantage of the company’s customers.

The increasing dovetailing of markets in the fields of diagnostics and biotechnology continues to provide STRATEC with the opportunity of drawing on its existing expertise to expand its activities beyond its primary markets.

The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical AG and subsidiaries and second-tier subsidiaries in Germany, USA, UK, Switzerland and Romania.